Akèy › Myelom Miltip › Wisconsin › Milwaukee
Etid klinik pou Myelom Miltip nan Milwaukee, WI
21 etid pou Myelom Miltip ap chèche patisipan nan sit nan ak bò kote Milwaukee (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Ap rekriteFaz 3
- Research Site, Milwaukee
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Ap rekriteFaz 1/2
- Medical College of Wisconsin, Milwaukee
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 3
- Medical College Of Wisconsin, Milwaukee
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Ap rekriteFaz 4
- Froedtert Memorial, Milwaukee
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1/2
- The Medical College of Wisconsin, Milwaukee
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Ap rekriteFaz 2
- Aurora Cancer Care Milwaukee, Milwaukee
- Aurora St. Luke's Medical Center, Milwaukee
- Aurora Sinai Medical Center, Milwaukee
- ak 4 plis
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Ap rekriteFaz 3
- Medical College of Wisconsin, Milwaukee
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Ap rekriteFaz 3
- Medical College of Wisconsin, Milwaukee
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1/2
- Research Site, Milwaukee
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Ap rekriteFaz 3
- Aurora Cancer Care-Milwaukee, Milwaukee
- Ascension Southeast Wisconsin Hospital-Saint Joseph-Milwaukee, Milwaukee
- Ascension Columbia Saint Mary's Hospital-Milwaukee Campus, Milwaukee
- ak 13 plis
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Ap rekriteFaz 1/2
- Research Site, Milwaukee
Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma
Ap rekriteFaz 1
- Froedtert & the Medical College of Wisconsin, Milwaukee
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Ap rekriteFaz 2
- MCW-Clinical Cancer Center at Froedtert Hospital Campus, Milwaukee
Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
Ap rekrite
- Medical College of Wisconsin, Milwaukee
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Ap rekriteFaz 3
- Froedtert Memorial Lutheran Hospital, Milwaukee
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Ap rekriteFaz 2
- Medical College of Wisconsin, Milwaukee
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Ap rekriteFaz 1
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
Ap rekriteFaz 2
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
Ap rekriteFaz 1
- Froedtert & the Medical College of Wisconsin, Milwaukee
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Ap rekriteEtid obsèvasyon
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Ap rekriteFaz 1
- Froedtert and the Medical College of Wisconsin, Milwaukee
Etid Myelom Miltip nan lòt vil
- New York City, NY60 etid
- Boston, MA42 etid
- Atlanta, GA41 etid
- Houston, TX38 etid
- Durham, NC37 etid
- Nashville, TN32 etid
- Denver, CO27 etid
- Rochester, MN24 etid
- St. Louis, MO24 etid
- Columbus, OH24 etid
- Baldwin Park, CA23 etid
- Chicago, IL22 etid
Lòt etid nan Milwaukee
- Kansè nan tete23 etid
- Kansè Poumon ki pa ti selil22 etid
- Kansè (tout kalite)22 etid
- Kansè poumon21 etid
- Kansè pwostat20 etid
- Limfòm folikilè19 etid
- Kansè pankreyas18 etid
- Limfòm Non-Hodgkin18 etid
- Kansè ovè17 etid
- Leksemi mieloïd egi17 etid
- Limfòm Burkitt16 etid
- Ensifizyans kadyak16 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.